Healio
Healio

Read more

September 30, 2020
1 min read
Save

Nine important updates for Gynecologic Cancer Awareness Month

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

September is Gynecologic Cancer Awareness Month, an awareness campaign launched in 1999 by Foundation for Women’s Cancer.

The campaign is intended to educate women about risk factors, symptoms, prevention and detection of cervical, ovarian, endometrial, uterine and vulvar malignancies.

3d illustration of ovarian cancer
Source: Adobe Stock.

In conjunction with this observance, Healio and HemOnc Today provide the following important updates in gynecologic cancer screening and treatment.

  • The FDA granted fast track designation to XMT-1536 (Mersana Therapeutics) for the treatment of certain women with high-grade serous ovarian cancer. Read more.
  • The addition of trastuzumab (Herceptin, Genentech) to carboplatin and paclitaxel increased PFS and OS for women with advanced or recurrent HER2-positive uterine serous carcinoma. Read more.
  • An updated guideline issued by American Cancer Society recommends cervical cancer screening with the HPV test every 5 years from age 25 years to 65 years. Read more.
  • A new guideline issued by American Society for Radiation Oncology addresses the use of radiation therapy for the treatment of nonmetastatic cervical cancer. Read more.
  • The addition of berzosertib (VE-822, Merck) to gemcitabine extended PFS for women with platinum-resistant, high-grade serous ovarian cancer. Read more.
  • Lipophilic statins appeared associated with reduced mortality among women with ovarian cancer. Read more.
  • Minimally invasive surgical procedures appeared associated with an elevated risk for recurrence or death compared with open surgery among women with early-stage gynecologic cancers. Read more.
  • Secondary cytoreductive surgery conferred significant and clinically meaningful OS and PFS benefits for selected women with recurrent ovarian cancer. Read more.
  • Maintenance therapy with olaparib (Lynparza; AstraZeneca, Merck) extended OS compared with placebo among women with platinum-sensitive, BRCA-mutated relapsed ovarian cancer. Read more.
Sources/Disclosures

Collapse
Source:

Healio Coverage

Read more about

gynecologic cancer
women's health
ovarian cancer
advanced high-grade serous carcinoma
human papilloma virus
berzosertib
olaparib
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

 

Related Content